Optimizing Immunotherapy for Lung Cancer: Integrating Genetic Alterations and the Tumor Mutational Burden to Refine Patient Selection

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2025 Feb 20

PMID 39974381

Authors

Takahiro Sugawara

Taiki Hakozaki

Masahiro Seike

Yukio Hosomi

Affiliations

Soon will be listed here.

References

Huang R, Huang Y, An N, Hu J, Wu C, Chen Y . Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure. ESMO Open. 2024; 9(7):103494. PMC: 11292426. DOI: 10.1016/j.esmoop.2024.103494. View

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

Wallenta Law J, Bapat B, Sweetnam C, Mohammed H, McBratney A, Izano M . Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer. JCO Precis Oncol. 2024; 8:e2400075. PMC: 11371096. DOI: 10.1200/PO.24.00075. View

Facchinetti F, Bluthgen M, Tergemina-Clain G, Faivre L, Pignon J, Planchard D . LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer. 2017; 112:62-68. DOI: 10.1016/j.lungcan.2017.08.002. View

Hellmann M, Nathanson T, Rizvi H, Creelan B, Sanchez-Vega F, Ahuja A . Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018; 33(5):843-852.e4. PMC: 5953836. DOI: 10.1016/j.ccell.2018.03.018. View

Vanguri R, Luo J, Aukerman A, Egger J, Fong C, Horvat N . Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nat Cancer. 2022; 3(10):1151-1164. PMC: 9586871. DOI: 10.1038/s43018-022-00416-8. View

Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles J . Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002; 62(13):3659-62. View

Imielinski M, Berger A, Hammerman P, Hernandez B, Pugh T, Hodis E . Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150(6):1107-20. PMC: 3557932. DOI: 10.1016/j.cell.2012.08.029. View

10.

Garon E, Hellmann M, Rizvi N, Carcereny E, Leighl N, Ahn M . Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019; 37(28):2518-2527. PMC: 6768611. DOI: 10.1200/JCO.19.00934. View

11.

Kobayashi Y, Lim S, Yamaguchi H . Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. Semin Cancer Biol. 2019; 65:51-64. DOI: 10.1016/j.semcancer.2019.11.011. View

12.

Garassino M, Cho B, Kim J, Mazieres J, Vansteenkiste J, Lena H . Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018; 19(4):521-536. PMC: 7771363. DOI: 10.1016/S1470-2045(18)30144-X. View

13.

van de Haar J, Mankor J, Hummelink K, Monkhorst K, Smit E, Wessels L . Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer. Clin Cancer Res. 2024; 30(7):1307-1318. PMC: 10982639. DOI: 10.1158/1078-0432.CCR-23-4027. View

14.

Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J . EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann Oncol. 2019; 30(8):1311-1320. PMC: 6683857. DOI: 10.1093/annonc/mdz141. View